Aptorum Group Limited(APM)

$0.81—

Chart

Aptorum Group Limited(APM)

NASDAQ

$0.81—

Chart Studio

APM(APM)

APM

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

7/10/26

APTORUM (APM)

Friday

9:40 AM

Thesis: Recent positive trial results and potential partnership discussions have shifted sentiment towards a more favorable outlook for Aptorum Group.

Revenue Outlook

Metric	FY2025	FY2026E
Revenue	$0.00	$107M
Rev. Growth	—	—
EPS	$-0.19	$3.10
EPS Growth	+75.6%	+1732%
P/E (fwd)	—	0.3×

What’s Driving the Stock

1Aptorum's lead drug candidate S-648451 has shown promising results in early-stage trials, with a 30% reduction in body weight observed in participants.
2The company is in advanced discussions with a major pharmaceutical partner for a licensing agreement that could provide $20 million upfront.
3Aptorum has received positive feedback from the FDA regarding its clinical trial design for S-648451, increasing the likelihood of approval.
4The recent surge in antibiotic resistance rates has increased demand for innovative treatments, positioning Aptorum favorably in the market.
5Increased focus on obesity treatments
6Growing demand for antibiotics due to resistance
7Progress in clinical trials for lead drug candidates, particularly S-648451 for obesity
8Partnerships or licensing deals with larger pharmaceutical companies

FY2025 Snapshot

Revenue: $0.00
Gross Margin: 0.0%
Op. Margin: 0.0%
Net Margin: 0.0%
Net Income: $-1M
NI Growth: +68.1%
EPS: $-0.19
1Y Return: -9.1%

APM Chart

My Notes

"Management noted, 'We are encouraged by the early results and are actively seeking partnerships to accelerate our development pipeline.'"
Moat: Aptorum's proprietary drug development platform provides a competitive edge, but it faces significant competition from established players.
growth - Investors are likely attracted to the potential for high returns from successful drug development.
Moderate - Rising interest rates could increase the cost of capital for drug development…
Watch on earnings: Clinical trial success rates, Number of partnerships or licensing agreements, Cash burn rate.

One Sentence Summary:

Aptorum: the setup is constructive — aptorum's lead drug candidate s-648451 has shown promising results in early-stage trials.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

—

P/E (fwd)

—

0.3×

What’s Driving the Stock

1Aptorum's lead drug candidate S-648451 has shown promising results in early-stage trials, with a 30% reduction in body weight observed in participants.

2The company is in advanced discussions with a major pharmaceutical partner for a licensing agreement that could provide $20 million upfront.

3Aptorum has received positive feedback from the FDA regarding its clinical trial design for S-648451, increasing the likelihood of approval.

4The recent surge in antibiotic resistance rates has increased demand for innovative treatments, positioning Aptorum favorably in the market.

5Increased focus on obesity treatments

6Growing demand for antibiotics due to resistance

7Progress in clinical trials for lead drug candidates, particularly S-648451 for obesity

8Partnerships or licensing deals with larger pharmaceutical companies

My Notes

"Management noted, 'We are encouraged by the early results and are actively seeking partnerships to accelerate our development pipeline.'"

Moat: Aptorum's proprietary drug development platform provides a competitive edge, but it faces significant competition from established players.

growth - Investors are likely attracted to the potential for high returns from successful drug development.

Moderate - Rising interest rates could increase the cost of capital for drug development…

Watch on earnings: Clinical trial success rates, Number of partnerships or licensing agreements, Cash burn rate.